title: Actions of GnRH antagonists on IGF-II, IGF-binding protein-2 and pregnancy-associated plasma protein-A in human granulosa-lutein cells.
abstract: OBJECTIVE
  Recently, GnRH antagonists (GnRHants) have been introduced for the prevention of premature LH surges during controlled ovarian hyperstimulation (COH). Here we investigated whether the GnRHants cetrorelix and ganirelix exert effects on the human ovarian IGF system. Since controversy exists on the action of GnRH agonists in the human ovary, we also tested the effect of triptorelin on IGF-II, IGF-binding protein-2 (IGFBP-2) and pregnancy-associated plasma protein-A (PAPP-A) in cultured human granulosa-lutein cells.
  
  
  METHODS
  In vitro cell culture study in a research laboratory of a university hospital.
  
  
  METHODS
  Cells were obtained from patients treated with different protocols of COH. In addition to gonadotropins they received triptorelin or cetrorelix. Cells were treated with triptorelin, cetrorelix or ganirelix, 1 nmol/l each, for 48 h. IGF-II, IGFBP-2 and PAPP-A were measured by RIA and enzyme immunoassay respectively.
  
  
  RESULTS
  GnRHants and triptorelin did not affect IGF-II, IGFBP-2 or PAPP-A.
  
  
  CONCLUSIONS
  We conclude that GnRHants do not exert any significant effects on the IGF system of granulosa-lutein cells and therefore their introduction into protocols of COH is unlikely to impair ovarian function.
authors.affiliation: Department of Obstetrics and Gynecology, Medical University Lubeck, 23538 Lubeck, Germany. jmweiss1@hotmail.com
authors.forename: J M
authors.initials: JM
authors.lastname: Weiss
authors.forename: B
authors.initials: B
authors.lastname: Krautmacher
authors.forename: S
authors.initials: S
authors.lastname: Polack
authors.forename: K
authors.initials: K
authors.lastname: Diedrich
authors.forename: O
authors.initials: O
authors.lastname: Ortmann
mesh_terms: D002478:Cells, Cultured; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D006107:Granulosa Cells / Q000737:chemistry / Q000166:cytology / Q000187:drug effects*; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000032:analysis*; D007335:Insulin-Like Growth Factor II / Q000032:analysis*; D008186:Luteolytic Agents / Q000494:pharmacology; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis*; D017329:Triptorelin Pamoate / Q000494:pharmacology
chemical_list: D006727:Hormone Antagonists; D018971:Insulin-Like Growth Factor Binding Protein 2; D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D007335:Insulin-Like Growth Factor II; D011266:Pregnancy-Associated Plasma Protein-A; C061018:ganirelix; C062876:cetrorelix